<DOC>
	<DOCNO>NCT02148133</DOCNO>
	<brief_summary>This open-label , non-randomized , phase II study ass efficacy safety eltrombopag Japanese moderate severe aplastic anemia ( AA ) subject platelet count &lt; 30,000/ microliter refractory anti-thymocyte globulin ( ATG ) -based immunosuppressive therapy ( IST ) , relapse ATG-based IST , ineligible ATG-based IST . Eltrombopag expect improve trilineage blood cell decrease transfusion frequency base result previous study patient severe AA . This study use hematologic response rate , define proportion subject show improvement least one three blood cell lineages decrease blood transfusion volume , primary endpoint . Twenty patient enrol study . Treatment eltrombopag start 25 milligram ( mg ) /day increase 25 mg/day every 2 week accord platelet count 100 mg/day . Response assessment perform 3 month start study treatment ( Week 13 ) . Subjects treatment assess effective continued study treatment . Subjects treatment assessed effective ( meet response criterion ) 6 month start study treatment ( Week 26 ) may enter extension phase continue treatment eltrombopag . The primary endpoint hematologic response rate Week26 .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Eltrombopag Japanese Subjects With Refractory , Moderate More Severe Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Subject give write informed consent . If subject 20 year , subject subject 's legally acceptable representative give inform consent . Japanese subject age &gt; =18 &lt; 80 year time inform consent . Diagnosis moderate ( stage II ) Aplastic Anemia ( AA ) platelet count &lt; 30,000/microliter ( base diagnosis criterion AA establish Study Group Idiopathic Hematopoietic Disorder part Research Measures Intractable Diseases support Health Labor Science Research Grants ) . Subjects become refractory Antithymocyte globulin ( ATG ) base Immunosuppressive therapy ( IST ) , relapse ATGbased IST , ineligible ATGbased IST . Note : Refractory relapse subject retreatment ATG indicate enrol study . Subjects sibling donor match human leukocyte antigen ( HLA ) enrol study . However , subject may enrol disease relapse hematopoietic stem cell transplantation ( HSCT ) , HSCT indicate , subject want undergo HSCT . Adequate organ function screen Day 1 define follow : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; =3 × central laboratory upper limit normal ( ULN ) ; Creatinine , total bilirubin , alkaline phosphatase ( ALP ) &lt; 1.5 × central laboratory ULN ( total bilirubin &lt; 2.5 × central laboratory ULN Gilbert 's Syndrome ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) : 0 1 Subjects QT interval correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 millisecond ( msec ) QTcF &lt; 480 msec branch block . Corrected QT interval duration ( QTc ) QT interval correct Fridericia formula ( QTcF ) , machine manual read . QTcF base single average QTc value triplicate electrocardiogram ( ECG ) . Subjects meet one follow condition : Male subject female partner childbearing potential must either prior vasectomy agree use acceptable contraception time enrollment study 16 week last dose eltrombopag ( base upon lifecycle sperm ) ; Female subject nonchildbearing potential ( physiologically unable become pregnant ) define : Premenopausal woman document bilateral oophorectomy , bilateral tubal ligation , hysterectomy ; postmenopausal woman least 12 month natural amenorrhea [ uncertain , postmenopausal state confirm hematology result follicle stimulate hormone ( FSH ) &gt; 40 milli international unit /milliliter ( mIU/mL ) estradiol &lt; 40 picogram ( pg ) /mL ( &lt; 140 picomole /Liter ( pmole/L ) ] . ; Female subject childbearing potential : Defined meeting definition nonchildbearing potential . Female subject childbearing potential must negative serum human chorionic gonadotropin ( hCG ) urine pregnancy test within 7 day prior first dose study treatment . It recommend pregnancy test perform close possible first dose study treatment . Female subject positive pregnancy test must exclude study . Subjects negative pregnancy test must use acceptable contraception include abstinence pregnancy test . Subjects must agree use acceptable contraception include abstinence 14 day prior first dose study treatment 28 day last dose eltrombopag . Treatment ATG past 12 month . Note : Subjects receive cyclosporine anabolic steroid ( exclude danazol ) stable dose may enrol laboratory value stable screening . Congenital aplastic anemia ( e.g. , Fanconi anemia , congenital dyskeratosis ) Paroxysmal nocturnal hemoglobinuria ( PNH ) granulocyte clone size determine flow cytometry &gt; =50 % Presence chromosomal aberration ( 7/7q detect fluorescence situ hybridization ( FISH ) , aberration detect Giemsa ( G ) band stain ) Note : Subjects result Gband staining ( bone marrow aspiration ) adopt abnormal clone definition An International System Human Cytogenetic Nomenclature ( ISCN ) enrol chromosomal aberration . Past history thromboembolism current use anticoagulant . Note : Subjects antiphospholipid antibody syndrome ( APS ) enrol . Past current history malignant tumor . Note : Subjects history completely resect malignant tumor diseasefree 5 year eligible . Subjects test positive hepatitis B surface ( HBs ) antigen , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody screen . Note : Subjects inactive hepatitis B may enrol . Judgment inactive hepatitis B do GSK medical monitor . Subjects concurrent uncontrollable severe infection ( e.g. , sepsis ) Hepatic cirrhosis Cardiac disorder ( congestive heart disease New York Heart Association ( NYHA ) functional classification Grade II/III/IV ) , arrhythmia risk thrombosis ( e.g. , atrial fibrillation ) . Note : Subjects NYHA Grade II due cardiac disorder enrol NYHA Grade II due Aplastic Anemia ( AA ) may enrol . Alcohol drug abuse Pregnant woman ( positive serum urine pregnancy test within 7 day prior first dose study treatment ) lactate woman . Note : Female subject lactate eligible participate discontinue nurse prior first dose study treatment refrain nurse 5 day treatment completion . Past history immediate delay hypersensitivity compound chemically similar eltrombopag activator Treatment another investigational product within 30 day period 5fold long halflife investigational product , whichever longer , prior first dose eltrombopag Prior treatment eltrombopag , romiplostim , Thrombopoietin ( TPO ) receptor agonist Use prohibit concomitant medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Aplastic Anemia ( AA )</keyword>
	<keyword>Thrombopoietin</keyword>
</DOC>